中科生物(01237.HK)向韓宏及韓金髮行共7100萬股以將債務資本化
格隆匯8月22日丨中科生物(01237.HK)公吿,於2022年8月22日,公司與認購人A韓宏訂立認購協議I,據此,認購人A已有條件同意以資本化公司欠認購人A的債券I的剩餘未償還金額及其應計利息272.6萬港元的方式按認購價0.0768港元認購合共3550萬股新股。
同日,公司與認購人B韓金訂立認購協議II,據此,認購人B已有條件同意以資本化公司欠認購人B的債券II的剩餘未償還金額及其應計利息272.6萬港元的方式按認購價0.0768港元認購合共3550萬股新股。
認購股份總數佔公司現有已發行股本約8.35%,並佔公司經配發及發行總認購股份擴大後已發行股本約7.71%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.